Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection

Launched by QIANFOSHAN HOSPITAL · Sep 23, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the potential heart-related problems, known as cardiotoxicity, that may be caused by a medication called sodium arsenite chloride injection. Researchers want to understand how often these heart issues occur, what factors might increase the risk, and how to prevent or manage these side effects. They will do this by reviewing past research, patient data, and real-world experiences from people who have used this medication.

To participate in the study, individuals must have received sodium arsenite chloride injection between January 1, 2012, and December 31, 2022. The trial is open to people of all ages and genders, but only those with complete medical information will be included. Participants can expect to share their experiences and medical history, which will help researchers gain a better understanding of the risks associated with this treatment. If you or a loved one have used this medication, this study could provide valuable insights into its safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • the period of consultation (for inpatients, according to the time of admission) is from January 1, 2012 to December 31, 2022
• • the patient used arsenite sodium chloride injection
• Exclusion Criteria:
• • Patients with incomplete clinical information